Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET

NCT03432741 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03432741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03432741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Terminated
Start date
March 27, 2018
Completion date
October 3, 2022
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast adenocarcinoma, metastatic breast carcinoma, recurrent breast carcinoma, recurrent hodgkin lymphoma, recurrent mycosis fungoides, recurrent non-hodgkin lymphoma, recurrent primary cutaneous t-cell non-hodgkin lymphoma, refractory breast carcinoma, refractory hodgkin lymphoma, refractory mycosis fungoides, refractory nodal marginal zone lymphoma, refractory non-hodgkin lymphoma, refractory primary cutaneous t-cell non-hodgkin lymphoma, stage iv breast cancer ajcc v6 and v7